In select patients with clinical and imaging features suggestive of RET+ NSCLC—and in the absence of other well-validated targets such as EGFR or BRAF mutations, ALK or ROS1 fusions on initial genotyping—it would be prudent to consider further testing for RET fusions so as to potentially expand effective treatment options for these patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.